Calcium-independent phospholipase A2, ELISA Kit

For Research Use Only. Not for use in diagnostic procedures.

Store all reagents at 2-8 degree C.

We suggest pre-experimenting with neat (undiluted) samples, 1:2 or 1:4 dilutions. Please avoid diluting your samples more than 1:10 as it would exceed the dilution limit set for this kit. If the expected concentration of the target is beyond the detection range of the kit, please contact our technical support team

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of PNPLA8 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS7249507 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Calcium-independent phospholipase A2 (PNPLA8) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing PNPLA8. The ELISA analytical biochemical technique of the MBS7249507 kit is based on PNPLA8 antibody-PNPLA8 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect PNPLA8 antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, PNPLA8. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

46,484 Da

phospholipase A2, group VI (cytosolic, calcium-independent)

85/88 kDa calcium-independent phospholipase A2; GVI PLA2; iPLA2-beta; group VI phospholipase A2; 85 kDa calcium-independent phospholipase A2; patatin-like phospholipase domain containing 9; cytosolic, calcium-independent phospholipase A2; neurodegeneration with brain iron accumulation 2; patatin-like phospholipase domain-containing protein 9; intracellular membrane-associated calcium-independent phospholipase A2 beta

85/88 kDa calcium-independent phospholipase A2

PLPLA9; CaI-PLA2; GVI PLA2; iPLA2-beta; PNPLA9  [Similar Products]

PLPL9_HUMAN

The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010]

PLA2G6: Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F- actin polymerization at the pseudopods. Defects in PLA2G6 are the cause of neurodegeneration with brain iron accumulation type 2B (NBIA2B). A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive extrapyramidal dysfunction leading to rigidity, dystonia, dysarthria and sensorimotor impairment. Defects in PLA2G6 are the cause of neurodegeneration with brain iron accumulation type 2A (NBIA2A); also known as Seitelberger disease. NBIA2A is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years. Defects in PLA2G6 are the cause of Parkinson disease type 14 (PARK14). An *****-onset progressive neurodegenerative disorder characterized by parkinsonism, dystonia, severe cognitive decline, cerebral and cerebellar atrophy and absent iron in the basal ganglia on magnetic resonance imaging. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: EC 3.1.1.4; Phospholipase; Lipid Metabolism - arachidonic acid; Lipid Metabolism - ether lipid; Lipid Metabolism - alpha-linolenic acid; Lipid Metabolism - linoleic acid; Lipid Metabolism - glycerophospholipid

Chromosomal Location of Human Ortholog: 22q13.1

Cellular Component: mitochondrion; membrane; cytoplasm; microtubule organizing center; cytosol

Molecular Function: calmodulin binding; phospholipase A2 activity; ATP-dependent protein binding; calcium-independent phospholipase A2 activity

Biological Process: cardiolipin biosynthetic process; urinary bladder smooth muscle contraction; maternal process involved in pregnancy; glycerophospholipid biosynthetic process; negative regulation of synaptic transmission, glutamatergic; chemotaxis; positive regulation of vasodilation; memory; elevation of cytosolic calcium ion concentration; phospholipid metabolic process; innate immune response; positive regulation of protein amino acid phosphorylation; lipid catabolic process; positive regulation of exocytosis

Disease: Parkinson Disease 14, Autosomal Recessive; Neurodegeneration With Brain Iron Accumulation 2b; Neurodegeneration With Brain Iron Accumulation 2a

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.